Avalyn Pharma Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-03-10: Study NCT07194382; Company role Lead sponsor; Phase Phase 2; Status Recruiting.
- 2025-04-17: Study NCT06951217; Company role Lead sponsor; Phase Phase 2; Status Recruiting.
- 2024-04-03: Study NCT06329401; Company role Lead sponsor; Phase Phase 2; Status Active not recruiting.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-03-10 | NCT07194382 AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF | Lead sponsor | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 160 | 2027-06 |
| 2025-04-17 | NCT06951217 An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) | Lead sponsor | Phase 2 | Recruiting | Progressive Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF) | 340 | 2031-12-31 |
| 2024-04-03 | NCT06329401 A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis | Lead sponsor | Phase 2 | Active not recruiting | Pulmonary Fibrosis; Progressive Pulmonary Fibrosis; Pulmonary Fibrosis Secondary to Systemic Sclerosis; Pulmonary Fibrosis, Interstitial Lung Disease; Interstitial Lung Disease; Interstitial Lung Disease Due to Connective Tissue Disease (Disorder); Interstitial Lung Disease in Patients With Rheumatoid Arthritis; Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere; Hypersensitivity Pneumonitis; Interstitial Lung Disease With Systemic Sclerosis | 375 | 2027-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B |